Market Closed -
Nasdaq
16:30:00 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
1.95
USD
|
-10.55%
|
|
-3.94%
|
-72.22%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
318.3
|
225
|
38
|
16.6
|
6.041
|
-
|
-
|
Enterprise Value (EV)
1 |
318.3
|
225
|
38
|
16.6
|
6.041
|
6.041
|
6.041
|
P/E ratio
|
-15.7
x
|
-7.1
x
|
-0.99
x
|
-0.59
x
|
-0.27
x
|
-0.26
x
|
-0.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
2,553
x
|
76.6
x
|
22.6
x
|
10.1
x
|
10.1
x
|
0.52
x
|
EV / Revenue
|
-
|
2,553
x
|
76.6
x
|
22.6
x
|
10.1
x
|
10.1
x
|
0.52
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-17,963,262
x
|
-6,872,299
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
889
|
1,015
|
1,448
|
2,365
|
3,098
|
-
|
-
|
Reference price
2 |
358.0
|
221.8
|
26.25
|
7.020
|
1.950
|
1.950
|
1.950
|
Announcement Date
|
21-03-10
|
22-03-24
|
23-03-31
|
24-03-28
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.0882
|
0.4958
|
0.7339
|
0.6
|
0.6
|
11.53
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.69
|
-31.79
|
-31.8
|
-21.89
|
-23.71
|
-31.23
|
-25.97
|
Operating Margin
|
-
|
-36,055.65%
|
-6,413.1%
|
-2,983.45%
|
-3,951.5%
|
-5,205.67%
|
-225.31%
|
Earnings before Tax (EBT)
1 |
-18.57
|
-31.04
|
-31.77
|
-21.24
|
-23.67
|
-31.15
|
-25.85
|
Net income
1 |
-18.57
|
-31.04
|
-31.77
|
-21.24
|
-23.67
|
-31.15
|
-25.85
|
Net margin
|
-
|
-35,207.25%
|
-6,407.71%
|
-2,894.69%
|
-3,944.83%
|
-5,192.33%
|
-224.26%
|
EPS
2 |
-22.75
|
-31.25
|
-26.50
|
-11.85
|
-7.280
|
-7.510
|
-5.930
|
Free Cash Flow
|
-17.72
|
-32.75
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-37,145.04%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-10
|
22-03-24
|
23-03-31
|
24-03-28
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.05
|
0.012
|
0.0674
|
0.028
|
0.0876
|
0.3128
|
0.0514
|
0.3334
|
0.2348
|
0.1143
|
0.15
|
0.15
|
0.15
|
0.15
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-8.678
|
-10.1
|
-8.44
|
-8.773
|
-7.281
|
-7.381
|
-7.086
|
-5.019
|
-4.421
|
-5.369
|
-5.447
|
-5.565
|
-6.064
|
-6.634
|
Operating Margin
|
-17,355.16%
|
-84,136.67%
|
-12,515.36%
|
-31,331.46%
|
-8,312.16%
|
-2,359.74%
|
-13,778.83%
|
-1,505.6%
|
-1,883.03%
|
-4,695.8%
|
-3,631.33%
|
-3,710%
|
-4,042.67%
|
-4,422.67%
|
Earnings before Tax (EBT)
1 |
-8.679
|
-10.05
|
-8.376
|
-8.746
|
-7.274
|
-7.373
|
-7.051
|
-5.02
|
-4.409
|
-4.762
|
-5.437
|
-5.555
|
-6.054
|
-6.624
|
Net income
1 |
-8.679
|
-10.05
|
-8.376
|
-8.746
|
-7.274
|
-7.373
|
-7.051
|
-5.02
|
-4.409
|
-4.762
|
-5.437
|
-5.555
|
-6.054
|
-6.624
|
Net margin
|
-17,357.32%
|
-83,748.08%
|
-12,419.93%
|
-31,236.89%
|
-8,305.17%
|
-2,357.32%
|
-13,710.62%
|
-1,505.99%
|
-1,878.19%
|
-4,165.49%
|
-3,624.67%
|
-3,703.33%
|
-4,036%
|
-4,416%
|
EPS
2 |
-8.500
|
-10.00
|
-8.750
|
-8.500
|
-7.250
|
-2.500
|
-4.750
|
-3.500
|
-2.250
|
-11.44
|
-2.200
|
-2.110
|
-1.530
|
-1.680
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-15
|
22-03-24
|
22-05-11
|
22-08-11
|
22-11-14
|
23-03-31
|
23-05-11
|
23-08-14
|
23-11-14
|
24-03-28
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-17.7
|
-32.7
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.1
|
0.87
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
985.15%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-10
|
22-03-24
|
23-03-31
|
24-03-28
|
-
|
-
|
-
|
Last Close Price
1.95
USD Average target price
36
USD Spread / Average Target +1,746.15% Consensus |
1st Jan change
|
Capi.
|
---|
| -72.22% | 6.04M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|